Insiders of Chemaphor Inc. announce acquisition of common shares and common
share purchase warrants

OTTAWA, Oct. 27 /CNW Telbec/ - As disclosed by Chemaphor Inc. ("Chemaphor") (TSX Venture Exchange: CFR) by press release dated as of October 23, 2009, Chemaphor has completed a private placement of common shares and common share purchase warrants. Purchasers participating in such private placement acquired one common share and one common share purchase warrant for $0.15.

Dr. Graham Burton, an officer and director of Chemaphor, participated in such private placement acquiring ownership or control over 1,319,279 common shares of Chemaphor and 1,319,279 common share purchase warrants, representing approximately 7.9% of the outstanding common shares of Chemaphor as of the closing of the private placement (assuming exercise of the acquired warrants). 529,553 of such common shares and an equal number of such common share purchase warrants were acquired by Dr. Burton's spouse Hedy Burton. Dr. Burton and his spouse previously owned a total of 835,244 common shares, 295,000 common share purchase warrants and 250,000 common share purchase options. Following this transaction Dr. Burton and his spouse hold a total of 2,154,523 common shares, 1,614,279 common share purchase warrants and 250,000 common share purchase options representing approximately 12.3% of the outstanding common shares of Chemaphor as of the closing of the private placement (assuming exercise of such warrants and options).

Dr. Janusz Daroszewski, an officer and director of Chemaphor, participated in such private placement acquiring ownership or control over 1,068,170 common shares of Chemaphor and 1,068,170 common share purchase warrants, representing approximately 6.5% of the outstanding common shares of Chemaphor as of the closing of the private placement (assuming exercise of the acquired warrants). 534,085 of such common shares and an equal number of the common share purchase warrants were acquired by Dr. Daroszewski's spouse Malgorzata Daroszewska. Dr. Daroszewski and his spouse previously owned a total of 835,244 common shares and 250,000 common share purchase options. Following this transaction Dr. Daroszewski and his spouse hold a total of 1,903,414 common shares, 1,068,170 common share purchase warrants and 250,000 common share purchase options representing approximately 10.1% of the outstanding common shares of Chemaphor as of the closing of the private placement (assuming exercise of such warrants and options).

Each of Dr. Burton and Dr. Daroszewski acquired the foregoing securities for investment purposes and acquired the securities in reliance on exemptions from securities legislation available to officers and directors of an issuer.

For additional detail on the terms of the private placement please refer to Chemaphor's press release dated October 23, 2009.

This press release is issued pursuant to the requirements of National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues - and the applicable Canadian securities legislation.

    
    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.
    

SOURCE CHEMAPHOR INC.

For further information: For further information: Dr. Graham Burton, (613) 990-0969

Organization Profile

CHEMAPHOR INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890